Top

Published in:

Open Access 01-12-2022 | COVID-19 | Review

Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride

Authors: Ignacio J. Ansotegui, Jonathan A. Bernstein, Giorgio W. Canonica, Sandra N. Gonzalez-Diaz, Bryan L. Martin, Mario Morais-Almeida, Margarita Murrieta-Aguttes, Mario Sanchez Borges

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2022

Abstract

Objective

The present narrative review provides a comprehensive update of the current knowledge on urticaria, both in adult and pediatric populations, and on the safety and efficacy of fexofenadine hydrochloride (HCl) as a treatment option.

Data source

A literature search was conducted on Embase and Medline.

Study selection

Clinical studies published in English and published between 1999 and 2020 were selected.

Results

Although the exact pathogenesis of urticaria is not fully understood, multiple pathways of mast cell activation are discussed to explain the existence of phenotypically different clinical manifestations of urticaria. An overview of the worldwide prevalence of chronic urticaria, including disease burden and patient’s quality of life is provided. The impact of urticaria on patient’s life differs on the basis of whether its form is acute or chronic, but pharmacological approaches are most often needed to control the disabling symptoms. A summary of the current management of urticaria recommended by different guidelines across countries (Global; European; American; Australian; Asian; Japanese) is presented. Non-sedating, second-generation H₁-antihistamines are the preferred choice of treatment across several guidelines worldwide. Herein, the efficacy and safety of fexofenadine HCl, a representative second-generation H₁-antihistamine approved for the treatment of urticaria, is discussed. The occurrence of urticaria manifestations in COVID-19 patients is also briefly presented.

Conclusion

The burden of acute and chronic urticaria is high for patients. Second generation anti-histamines such as fexofenadine HCl can help managing the symptoms.

Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, Bernstein JA, Bindslev-Jensen C, Brzoza Z, BuenseBedrikow R, Canonica GW, Church MK, Craig T, Danilycheva IV, Dressler C, Ensina LF, Giménez-Arnau A, Godse K, Gonçalo M, Grattan C, Hebert J, Hide M, Kaplan A, Kapp A, Katelaris CH, Kocatürk E, Kulthanan K, Larenas-Linnemann D, Leslie TA, Magerl M, Mathelier-Fusade P, Meshkova RY, Metz M, Nast A, Nettis E, Oude-Elberink H, Rosumeck S, Saini SS, Sánchez-Borges M, Schmid-Grendelmeier P, Staubach P, Sussman G, Toubi E, Vena GA, Vestergaard C, Wedi B, Werner RN, Zhao Z, Maurer M. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–414. https://doi.org/10.1111/all.13397.CrossRefPubMed

Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M, Zuberbier T, Keil T. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75(2):423–32. https://doi.org/10.1111/all.14037.CrossRefPubMed

Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, Mirakian R, Walker SM, Huber PAJ, Nasser SM. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;37(5):631–50. https://doi.org/10.1111/j.1365-2222.2007.02678.x.CrossRefPubMed

Saini S, Shams M, Bernstein JA, Maurer M. Urticaria and angioedema across the ages. J Allergy Clin Immunol Pract. 2020;8(6):1866–74. https://doi.org/10.1016/j.jaip.2020.03.030.CrossRefPubMed

Asero R, Tedeschi A, Marzano AV, Cugno M. Chronic urticaria: a focus on pathogenesis. F1000Res. 2017;6:1095. https://doi.org/10.12688/f1000research.11546.1.CrossRefPubMedPubMedCentral

Nettis E, Foti C, Ambrifi M, Baiardini I, Bianchi L, Borghi A, Caminati M, Canonica GW, Casciaro M, Colli L, Colombo G, Corazza M, Cristaudo A, De Feo G, De Pita’ O, Di Gioacchino M, Di Leo E, Fassio F, Gangemi S, Gatta A, Hansel K, Heffler E, Incorvaia C, Napolitano M, Patruno C, Peveri S, Pigatto PD, Quecchia C, Radice A, Ramirez GA, Romita P, Rongioletti F, Rossi O, Savi E, Senna G, Triggiani M, Zucca M, Maggi E, Stingeni L. Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology. Clin Mol Allergy. 2020;18(1):8. https://doi.org/10.1186/s12948-020-00123-8.CrossRefPubMedPubMedCentral

Poonawalla T, Kelly B. Urticaria: a review. Am J Clin Dermatol. 2009;10(1):9–21. https://doi.org/10.2165/0128071-200910010-00002.CrossRefPubMed

Zuberbier T, Ifflander J, Semmler C, Henz BM. Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol. 1996;76(4):295–7. https://doi.org/10.2340/0001555576295297.CrossRefPubMed

Williams PV. Pharmacologic management of chronic urticaria in pediatric patients: the gap between guidelines and practice. Pediatr Drugs. 2020;22(1):21–8. https://doi.org/10.1007/s40272-019-00365-3.CrossRef

10.

Kolkhir P, Altrichter S, Munoz M, Hawro T, Maurer M. New treatments for chronic urticaria. Ann Allergy Asthma Immunol. 2020;124(1):2–12. https://doi.org/10.1016/j.anai.2019.08.014.CrossRefPubMed

11.

Auyeung P, Mittag D, Hodgkin PD, Harrison LC. Autoreactive T cells in chronic spontaneous urticaria target the IgE Fc receptor Iα subunit. J Allergy Clin Immunol. 2016;138(3):761-768.e764. https://doi.org/10.1016/j.jaci.2016.04.036.CrossRefPubMed

12.

Gonzalez-Diaz SN, Sanchez-Borges M, Rangel-Gonzalez DM, Guzman-Avilan RI, Canseco-Villarreal JI, Arias-Cruz A. Chronic urticaria and thyroid pathology. WHO J. 2020;13(3): 100101. https://doi.org/10.1016/j.waojou.2020.100101.CrossRef

13.

Hennino A, Bérard F, Guillot I, Saad N, Rozières A, Nicolas J-F. Pathophysiology of urticaria. Clin Rev Allergy Immunol. 2006;30(1):3–11. https://doi.org/10.1385/CRIAI:30:1:003.CrossRefPubMed

14.

Grattan CE, Francis DM, Hide M, Greaves MW. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy. 1991;21(6):695–704. https://doi.org/10.1111/j.1365-2222.1991.tb03198.x.CrossRefPubMed

15.

Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med. 1993;328(22):1599–604. https://doi.org/10.1056/nejm199306033282204.CrossRefPubMed

16.

Sánchez J, Sánchez A, Cardona R. Causal relationship between anti-TPO IgE and chronic urticaria by in vitro and in vivo tests. Allergy Asthma Immunol Res. 2019;11(1):29–42.CrossRef

17.

Schmetzer O, Lakin E, Topal FA, Preusse P, Freier D, Church MK, Maurer M. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;142(3):876–82. https://doi.org/10.1016/j.jaci.2017.10.035.CrossRefPubMed

18.

Hatada Y, Kashiwakura J, Hayama K, Fujisawa D, Sasaki-Sakamoto T, Terui T, Ra C, Okayama Y. Significantly high levels of anti-dsDNA immunoglobulin E in sera and the ability of dsDNA to induce the degranulation of basophils from chronic urticaria patients. Int Arch Allergy Immunol. 2013;161(Suppl 2):154–8. https://doi.org/10.1159/000350388.CrossRefPubMed

19.

Zheng W, Wang J, Zhu W, Xu C, He S. Upregulated expression of substance P in basophils of the patients with chronic spontaneous urticaria: induction of histamine release and basophil accumulation by substance P. Cell Biol Toxicol. 2016;32(3):217–28. https://doi.org/10.1007/s10565-016-9330-4.CrossRefPubMed

20.

Metz M, Krull C, Hawro T, Saluja R, Groffik A, Stanger C, Staubach P, Maurer M. Substance P is upregulated in the serum of patients with chronic spontaneous urticaria. J Investig Dermatol. 2014;134(11):2833–6. https://doi.org/10.1038/jid.2014.226.CrossRefPubMed

21.

Cookson H, Grattan C. An update on mast cell disorders. Clin Med (Lond). 2016;16(6):580–3. https://doi.org/10.7861/clinmedicine.16-6-580.CrossRef

22.

Boyden SE, Desai A, Cruse G, Young ML, Bolan HC, Scott LM, Eisch AR, Long RD, Lee CC, Satorius CL, Pakstis AJ, Olivera A, Mullikin JC, Chouery E, Megarbane A, Medlej-Hashim M, Kidd KK, Kastner DL, Metcalfe DD, Komarow HD. Vibratory urticaria associated with a missense variant in ADGRE2. N Engl J Med. 2016;374(7):656–63. https://doi.org/10.1056/NEJMoa1500611.CrossRefPubMedPubMedCentral

23.

Farinazzo E, Dianzani C, Zalaudek I, Conforti C, Grabbe S, Goldust M. Synthesis of the data on COVID-19 skin manifestations: underlying mechanisms and potential outcomes. Clin Cosmet Investig Dermatol. 2021;14:991–7. https://doi.org/10.2147/ccid.S325552.CrossRefPubMedPubMedCentral

24.

Alam M, Lewis W, Harp J, Steele K, Rosenbach M, Micheletti RG. Cutaneous manifestations of COVID-19: characteristics, pathogenesis, and the role of dermatology in the pandemic. Cutis. 2021;107(4):209–15. https://doi.org/10.12788/cutis.0230.CrossRefPubMed

25.

Klimach A, Evans J, Stevens J, Creasey N. Rash as a presenting complaint in a child with COVID-19. Pediatr Dermatol. 2020;37(5):966–7. https://doi.org/10.1111/pde.14257.CrossRefPubMed

26.

Navaeifar MR, PoudinehGhazaghi M, Shahbaznejad L, Rouhanizadeh H, Abutalebi M, RanjbarVarandi M, Rezai MS. Fever with rash is one of the first presentations of COVID-19 in children: a case report. Int Med Case Rep J. 2020;13:335–40. https://doi.org/10.2147/imcrj.S262935.CrossRefPubMedPubMedCentral

27.

Criado PR, Pagliari C, Criado RFJ, Marques GF, Belda W Jr. What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab during COVID-19 or asymptomatic infections due to SARS-CoV-2? Dermatol Ther. 2020;33(6): e14068. https://doi.org/10.1111/dth.14068.CrossRefPubMed

28.

Algaadi SA. Urticaria and COVID-19: a review. Dermatol Ther. 2020. https://doi.org/10.1111/dth.14290.CrossRefPubMed

29.

Abuelgasim E, Dona ACM, Sondh RS, Harky A. Management of urticaria in COVID-19 patients: a systematic review. Dermatol Ther. 2021. https://doi.org/10.1111/dth.14328.CrossRefPubMed

30.

Galván Casas C, Català A, Carretero Hernández G, Rodríguez-Jiménez P, Fernández-Nieto D, Rodríguez-Villa Lario A, Navarro Fernández I, Ruiz-Villaverde R, Falkenhain-López D, Llamas Velasco M, García-Gavín J, Baniandrés O, González-Cruz C, Morillas-Lahuerta V, Cubiró X, FiguerasNart I, Selda-Enriquez G, Romaní J, Fustà-Novell X, Melian-Olivera A, RonceroRiesco M, Burgos-Blasco P, Sola Ortigosa J, Feito Rodriguez M, García-Doval I. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020;183(1):71–7. https://doi.org/10.1111/bjd.19163.CrossRefPubMedPubMedCentral

31.

Shahidi Dadras M, Rakhshan A, Diab R, Abdollahimajd F. SARS-CoV-2 infection as a potential triggering factor for urticarial vasculitis during pregnancy: a case report. Clin Case Rep. 2021;9(6): e04323. https://doi.org/10.1002/ccr3.4323.CrossRefPubMedPubMedCentral

32.

Najafzadeh M, Shahzad F, Ghaderi N, Ansari K, Jacob B, Wright A. Urticaria (angioedema) and COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(10):e568–70. https://doi.org/10.1111/jdv.16721.CrossRefPubMedPubMedCentral

33.

Quintana-Castanedo L, Feito-Rodríguez M, Valero-López I, Chiloeches-Fernández C, Sendagorta-Cudós E, Herranz-Pinto P. Urticarial exanthem as early diagnostic clue for COVID-19 infection. JAAD Case Rep. 2020;6(6):498–9. https://doi.org/10.1016/j.jdcr.2020.04.026.CrossRefPubMedPubMedCentral

34.

Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol. 2020;34(6):e244–5. https://doi.org/10.1111/jdv.16472.CrossRefPubMedPubMedCentral

35.

Ahouach B, Harent S, Ullmer A, Martres P, Bégon E, Blum L, Tess O, Bachmeyer C. Cutaneous lesions in a patient with COVID-19: are they related? Br J Dermatol. 2020;183(2):e31–e31. https://doi.org/10.1111/bjd.19168.CrossRefPubMedPubMedCentral

36.

Falkenhain-López D, Sánchez-Velázquez A, López-Valle A, Ortiz-Frutos FJ. SARS-Coronavirus-2 and acute urticaria. Int J Dermatol. 2020;59(7):867–8. https://doi.org/10.1111/ijd.14950.CrossRefPubMedPubMedCentral

37.

Hassan K. Urticaria and angioedema as a prodromal cutaneous manifestation of SARS-CoV-2 (COVID-19) infection. BMJ Case Rep. 2020;13(7): e236981. https://doi.org/10.1136/bcr-2020-236981.CrossRefPubMedPubMedCentral

38.

Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Desai SR, Harp J, Takeshita J, French LE, Lim HW, Thiers BH, Hruza GJ, Fox LP. The spectrum of COVID-19-associated dermatologic manifestations: an international registry of 716 patients from 31 countries. J Am Acad Dermatol. 2020;83(4):1118–29. https://doi.org/10.1016/j.jaad.2020.06.1016.CrossRefPubMedPubMedCentral

39.

Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol. 2020;34(5):e212–3. https://doi.org/10.1111/jdv.16387.CrossRefPubMed

40.

De Giorgi V, Recalcati S, Jia Z, Chong W, Ding R, Deng Y, Scarfi F, Venturi F, Trane L, Gori A, Silvestri F, Gao XH, Lotti T. Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): a prospective study from China and Italy. J Am Acad Dermatol. 2020;83(2):674–5. https://doi.org/10.1016/j.jaad.2020.05.073.CrossRefPubMedPubMedCentral

41.

Nagashima S, Dutra AA, Arantes MP, Zeni RC, Klein CK, de Oliveira FC, Piper GW, Brenny ID, Pereira MRC, Stocco RB, Martins APC, de Castro EM, Vaz de Paula CB, Amaral ANM, Machado-Souza C, Baena CP, Noronha L. COVID-19 and lung mast cells: the Kallikrein-Kinin activation pathway. Int J Mol Sci. 2022;23(3):1714. https://doi.org/10.3390/ijms23031714.CrossRefPubMedPubMedCentral

42.

McGonagle D, Sharif K, O’Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6): 102537. https://doi.org/10.1016/j.autrev.2020.102537.CrossRefPubMedPubMedCentral

43.

Magro CM, Mulvey JJ, Laurence J, Sanders S, Crowson AN, Grossman M, Harp J, Nuovo G. The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol. 2021;184(1):141–50. https://doi.org/10.1111/bjd.19415.CrossRefPubMedPubMedCentral

44.

Maxim E, Aksut C, Tsoi D, Dellavalle R. Global burden of urticaria: insights from the 2016 Global Burden of Disease Study. J Am Acad Dermatol. 2018;79(3):567–9. https://doi.org/10.1016/j.jaad.2018.02.026.CrossRefPubMedPubMedCentral

45.

Gonçalo M, Gimenéz-Arnau A, Al-Ahmad M, Ben-Shoshan M, Bernstein JA, Ensina LF, Fomina D, Galvàn CA, Godse K, Grattan C, Hide M, Katelaris CH, Khoshkhui M, Kocatürk E, Kulthanan K, Medina I, Nasr I, Peter J, Staubach P, Wang L, Weller K, Maurer M. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021. https://doi.org/10.1111/bjd.19561.CrossRefPubMed

46.

Huang Y, Xiao Y, Zhang X, Li J, Chen X, Shen M. A meta-analysis of observational studies on the association of chronic urticaria with symptoms of depression and anxiety. Front Med (Lausanne). 2020;7:39–39. https://doi.org/10.3389/fmed.2020.00039.CrossRef

47.

Konstantinou GN, Konstantinou GN. Psychiatric comorbidity in chronic urticaria patients: a systematic review and meta-analysis. Clin Transl Allergy. 2019;9(1):42. https://doi.org/10.1186/s13601-019-0278-3.CrossRefPubMedPubMedCentral

48.

Hergüner S, Kiliç G, Karakoç S, Tamay Z, Tüzün U, Güler N. Levels of depression, anxiety and behavioural problems and frequency of psychiatric disorders in children with chronic idiopathic urticaria. Br J Dermatol. 2011;164(6):1342–7. https://doi.org/10.1111/j.1365-2133.2010.10138.x.CrossRefPubMed

49.

Hsieh P-Y, Chang C-Y, Chou C-C, Lin Y-R, Chen C-Y. Urticaria in adolescence increases the risk of developing new-onset depression: a database study. JACME. 2014;4(3):120–6. https://doi.org/10.1016/j.jacme.2014.06.002.CrossRef

50.

Staubach P, Dechene M, Metz M, Magerl M, Siebenhaar F, Weller K, Zezula P, Eckhardt-Henn A, Maurer M. High prevalence of mental disorders and emotional distress in patients with chronic spontaneous urticaria. Acta Derm Venereol. 2011;91(5):557–61. https://doi.org/10.2340/00015555-1109.CrossRefPubMed

51.

Delong LK, Culler SD, Saini SS, Beck LA, Chen SC. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol. 2008;144(1):35–9. https://doi.org/10.1001/archdermatol.2007.5.CrossRefPubMed

52.

Balp M-M, Abuzakouk M, Berard F, Canonica G.W, Gimenez-Arnau A, Hollis K, Khalil S, Knulst A.C, Lacour J-P, Lynde C, Marsland A, Maurer M, McBride D, Nakonechna A, Ortiz de Frutoz FJ, Oude Elberink J.N.G, Proctor C, Sussman G, Weller K, Grattan C (2016) Comparison of direct healthcare costs associated with chronic spontaneous/idiopathic urticaria in 7 countries: Results from th ASSURE-CSU study Paper presented at the ISPOR Vienna, 29 October.

53.

Maurer M, Abuzakouk M, Bérard F, Canonica W, Oude Elberink H, Giménez-Arnau A, Grattan C, Hollis K, Knulst A, Lacour JP, Lynde C, Marsland A, McBride D, Nakonechna A, Ortiz de Frutos J, Proctor C, Sussman G, Sweeney C, Tian H, Weller K, Wolin D, Balp MM. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005–16. https://doi.org/10.1111/all.13209.CrossRefPubMed

54.

Sánchez-Borges M, González-Díaz SN, Ortega Martel JA, Rojo I, IJ AZ (2020) Management of severe chronic urticaria: current and future therapies. Clin Trials 10(6)

55.

Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, Sheikh J, Weldon D, Zuraw B, Bernstein DI, Blessing-Moore J, Cox L, Nicklas RA, Oppenheimer J, Portnoy JM, Randolph CR, Schuller DE, Spector SL, Tilles SA, Wallace D. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270–7. https://doi.org/10.1016/j.jaci.2014.02.036.CrossRefPubMed

56.

Chow SKW. Management of chronic urticaria in Asia: 2010 AADV consensus guidelines. Asia Pac Allergy. 2012;2(2):149–60. https://doi.org/10.5415/apallergy.2012.2.2.149.CrossRefPubMedPubMedCentral

57.

Perera E, Sinclair R. Evaluation, diagnosis and management of chronic urticaria. Aust Fam Phys. 2014;43:621–5.

58.

Hide M. Japanese guidelines for diagnosis and treatment of urticaria, 2018. Arerugi [Allergy]. 2018;67(10):1394–8. https://doi.org/10.15036/arerugi.67.1394.CrossRef

59.

Godse K, Patil A, Godse G. Urticaria and its management in the context of coronavirus disease-19 (COVID-19). IP Indian J Clin Exp Dermatol. 2020;6(2):102–4. https://doi.org/10.18231/j.ijced.2020.022.CrossRef

60.

Simons FE, Simons KJ. H1 antihistamines: current status and future directions. WHO J. 2008;1(9):145–55. https://doi.org/10.1097/WOX.0b013e318186fb3a.CrossRef

61.

Fitzsimons R, Van Der Poel LA, Thornhill W, Du Toit G, Shah N, Brough HA. Antihistamine use in children. Arch Dis Child. 2015;100(3):122–31. https://doi.org/10.1136/archdischild-2013-304446.CrossRef

62.

AdisInsight Drugs Fexofenadine - sanofi-aventis. AdisInsight Drugs. https://adisinsight.springer.com/drugs/800006524. Accessed February 2021

63.

Sanchez J, Zakzuk J, Cardona R. Prediction of five antihistamines efficacy in chronic spontaneous urticaria with conventional or higher doses, based on histamine wheal diameter change. Allergy. 2015;70:10. https://doi.org/10.1111/all.12715.CrossRef

64.

Huang CZ, Jiang ZH, Wang J, Luo Y, Peng H. Antihistamine effects and safety of fexofenadine: a systematic review and meta-analysis of randomized controlled trials. BMC Pharmacol Toxicol. 2019. https://doi.org/10.1186/s40360-019-0363-1.CrossRefPubMedPubMedCentral

65.

Maciel-Guerra H, Penha MÁ, Jorge MFS, Libório RdS, Carrijo ACNDA, Parise-Fortes MR, Miot HA. Suppression of wheal and flare in histamine test by the main H1 antihistamines commercialized in Brazil. An Bras Dermatol. 2018;93(2):233–7. https://doi.org/10.1590/abd1806-4841.20186807.CrossRefPubMedPubMedCentral

66.

Meltzer EO, Gillman SA. Efficacy of fexofenadine versus desloratadine in suppressing histamine-induced wheal and flare. Allergy Asthma Proc. 2007;28(1):67–73.CrossRef

67.

Tanizaki H, Ikoma A, Fukuoka M, Miyachi Y, Kabashima K. Effects of bepotastine and fexofenadine on histamine-induced flare, wheal and itch. Int Arch Allergy Immunol. 2012;158(2):191–5. https://doi.org/10.1159/000330663.CrossRefPubMed

68.

Purohit A, N’Gom AS, Deslandes B, Pauli G, Frossard N. Similar rapid onset of action and magnitude of effect of fexofenadine and cetirizine as assessed by inhibition of histamine-induced wheal-and-flare reaction. Ann Allergy Asthma Immunol. 2004;93(6):562–7.CrossRef

69.

Paul E, Berth-Jones J, Ortonne JP, Stern M. Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: a placebo-controlled, parallel-group, dose-ranging study. J Dermatol Treat. 1998;9(3):143–9. https://doi.org/10.3109/09546639809160545.CrossRef

70.

Kaplan AP, Spector SL, Meeves S, Liao Y, Varghese ST, Georges G. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study. Ann Allergy Asthma Immunol. 2005;94(6):662–9. https://doi.org/10.1016/s1081-1206(10)61325-7.CrossRefPubMed

71.

Fouad M, Ragab M. Effectiveness and safety of fexofenadine in chronic idiopathic urticaria: open-label noncomparative study in daily practice. Egypt J Dermatol Venerol. 2017;37(2):43–8. https://doi.org/10.4103/ejdv.ejdv_38_16.CrossRef

72.

Iriarte Sotés P, Armisén M, Usero-Bárcena T, Rodriguez Fernández A, Otero Rivas M, Gonzalez MT, Meijide Calderón A, Veleiro B (2020) Up-dosing antihistamines in chronic spontaneous urticaria: efficacy and safety. A systematic review of the literature. J Investig Allergol Clin Immunol. https://doi.org/10.18176/jiaci.0649.

73.

Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol. 2000;43(1):24–30.CrossRef

74.

Spector SL, Shikiar R, Harding G, Meeves S, Leahy MJ. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. Cutis. 2007;79(2):157–62.PubMed

75.

Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2000;84(5):517–22.CrossRef

76.

Finn AF Jr, Kaplan AP, Fretwell R, Qu R, Long J. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol. 1999;104(5):1071–8. https://doi.org/10.1016/s0091-6749(99)70091-6.CrossRefPubMed

77.

Olasińska-Wiśniewska A, Olasiński J, Grajek S. Cardiovascular safety of antihistamines. Postepy Dermatol Alergol. 2014;31(3):182–6. https://doi.org/10.5114/pdia.2014.43191.CrossRefPubMedPubMedCentral

78.

Pratt C, Brown AM, Rampe D, Mason J, Russell T, Reynolds R, Ahlbrandt R. Cardiovascular safety of fexofenadine HCl. Clin Exp Allergy. 1999;29(Suppl 3):212–6. https://doi.org/10.1046/j.1365-2222.1999.0290s3212.x.CrossRefPubMed

79.

Hindmarch I, Shamsi Z, Stanley N, Fairweather DB. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. British Br J Clin Pharmacol. 1999;48(2):200–6. https://doi.org/10.1046/j.1365-2125.1999.00993.x.CrossRef

80.

Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy. 2002;32(1):133–9. https://doi.org/10.1046/j.0022-0477.2001.01245.x.CrossRefPubMed

81.

Hiraoka K, Tashiro M, Grobosch T, Maurer M, Oda K, Toyohara J, Ishii K, Ishiwata K, Yanai K. Brain histamine H1 receptor occupancy measured by PET after oral administration of levocetirizine, a non-sedating antihistamine. Expert Opin Drug Saf. 2015;14(2):199–206. https://doi.org/10.1517/14740338.2015.989831.CrossRefPubMed

82.

Klyucharova A, Mendelevich V, Skorohodkina O. Effect of II generation antihistamines on cognitive functions of chronic urticaria patients. Allergy. 2012;67:496. https://doi.org/10.1111/all.12037.CrossRef

83.

Isomura T, Kono T, Hindmarch I, Kikuchi N, Murakami A, Inuzuka K, Kawana S. Central nervous system effects of the second-generation antihistamines marketed in Japan—review of inter-drug differences using the proportional impairment ratio (PIR). PLoS ONE. 2014;9(12): e114336. https://doi.org/10.1371/journal.pone.0114336.CrossRefPubMedPubMedCentral

84.

Inami A, Matsuda R, Grobosch T, Komamura H, Takeda K, Yamada Y, Miyake M, Hiraoka K, Maurer M, Yanai K, Tashiro M. A simulated car-driving study on the effects of acute administration of levocetirizine, fexofenadine, and diphenhydramine in healthy Japanese volunteers. Hum Psychopharmacol Clin Exp. 2016;31(3):167–77. https://doi.org/10.1002/hup.2524.CrossRef

85.

Bower EA, Moore JL, Moss M, Selby KA, Austin M, Meeves S. The effects of single-dose fexofenadine, diphenhydramine, and placebo on cognitive performance in flight personnel. Aviat Space Environ Med. 2003;74(2):145–52.PubMed

86.

Church MK, Weller K, Stock P, Maurer M. Chronic spontaneous urticaria in children: itching for insight. Pediatr Allergy Immunol. 2011;22(1 Pt 1):1–8. https://doi.org/10.1111/j.1399-3038.2010.01120.x.CrossRefPubMed

87.

Pite H, Wedi B, Borrego LM, Kapp A, Raap U. Management of childhood urticaria: current knowledge and practical recommendations. Acta Derm Venereol. 2013;93(5):500–8. https://doi.org/10.2340/00015555-1573.CrossRefPubMed

88.

Milgrom H, Kittner B, Lanier R, Hampel FC. Safety and tolerability of fexofenadine for the treatment of allergic rhinitis in children 2 to 5 years old. Ann Allergy Asthma Immunol. 2007;99(4):358–63. https://doi.org/10.1016/s1081-1206(10)60553-4.CrossRefPubMed

89.

Bernstein DI, Schoenwetter WF, Nathan RA, Storms W, Ahlbrandt R, Mason J. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1997;79(5):443–8. https://doi.org/10.1016/s1081-1206(10)63041-4.CrossRefPubMed

90.

Hampel F, Ratner P, Mansfield L, Meeves S, Liao Y, Georges G. Fexofenadine hydrochloride, 180 mg, exhibits equivalent efficacy to cetirizine, 10 mg, with less drowsiness in patients with moderate-to-severe seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91(4):354–61. https://doi.org/10.1016/s1081-1206(10)61682-1.CrossRefPubMed

91.

Meltzer EO, Scheinmann P, Rosado Pinto JE, Bachert C, Hedlin G, Wahn U, Finn AF Jr, Ruuth E. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis—a pooled analysis of three studies. Pediatr Allergy Immunol. 2004;15(3):253–60. https://doi.org/10.1111/j.1399-3038.2004.00167.x.CrossRefPubMed

92.

Segall N, Grubbe RE, Levy AL, Maloney MJ, Nayak AS, Kittner B, Quesada JT. Pharmacokinetics, safety and tolerability of an oral suspension of fexofenadine for children with allergic rhinitis. Allergy Asthma Proc. 2008;29(4):380–5. https://doi.org/10.2500/aap.2008.29.3136.CrossRefPubMed

Title: Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride
Authors: Ignacio J. Ansotegui
Jonathan A. Bernstein
Giorgio W. Canonica
Sandra N. Gonzalez-Diaz
Bryan L. Martin
Mario Morais-Almeida
Margarita Murrieta-Aguttes
Mario Sanchez Borges
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: COVID-19
Urticaria
Fexofenadine
Desloratadine
Published in: Allergy, Asthma & Clinical Immunology / Issue 1/2022
Electronic ISSN: 1710-1492
DOI: https://doi.org/10.1186/s13223-022-00677-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride

Abstract

Objective

Data source

Study selection

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Objective

Data source

Study selection

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2022

Understanding attitudes and obstacles to vaccination against COVID-19 in patients with primary immunodeficiency

Outcome of a de-labelling algorithm compared with results of penicillin (β-lactam) allergy testing

The use of dupilumab in severe atopic dermatitis during pregnancy: a case report

Fatal liver mass rupture in a common-variable-immunodeficiency patient with probable nodular regenerating hyperplasia

Comparison of circulating fibrocytes from non-asthmatic patients with seasonal allergic rhinitis between in and out of pollen season samples

Physician education on World Asthma Day aids in disease management during the COVID-19